| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
VECTORMUNE® ND
Record information and status
Record ID
115064
Status
Published
Date of creation
2019-07-25 16:17 UTC (austein.mcloughlin@cbd.int)
Date of publication
2019-07-25 16:17 UTC (austein.mcloughlin@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
VECTORMUNE® ND
Transformation event
HVT-F/NDV
Developer(s)
Dr Alexis Henry Gaetan Goux
President of CIBio
Ceva Saude Animal Ltda (CEVA)
Rua Manuel Joaquim Filho, 303 Pulinia - SP
Sao Paulo, Brazil
13140-000
Sao Paulo
Brazil
Phone:+551938337700
Email:alexisgoux@ceva.com
Description
VECTORMUNE® ND is vaccine against Newcastle disease (ND) and Marek's Disease (MD). The vaccine contains modified Turkey Herpesvirus (Marek's disease vaccine; serotype 3), expressing fusion protein from Newcastle disease virus.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Gallid herpesvirus 2
Point of collection or acquisition of the recipient organism
Turkey Herpesvirus serotype 3
Related LMOs
VECTORMUNE® HVT-NDV + Rispens
Dr Alexis Henry Gaetan Goux Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Characteristics of the transformation process
Vector
p45/p46PecF
Techniques used for the modification
  • Virus-mediated gene transfer
Genetic elements construct
 
CMV Early Enhancer
0.28 Kb
 
 
Beta-actin gene promoter
0.27 Kb
 
 
Fusion protein gene
1.66 Kb
 
 
SV40 poly-adenylation signal
0.33 Kb
 
Further details
Notes regarding the genetic elements introduced or modified in this LMO
The recombinant virus contains an expression cassette located in the intergenic region between genes UL45 and UL46 Turkey Herpesvirus (HVT). The recombinant virus was created by transfecting chick embryo fibroblast cells with wild-type HVT strain FC126 and the plasmid vector p45/46PecF. During viral packaging, recombination of the genetic material occurred due to the homologous sequences of UL45 and UL46 flanking the expression cassette in the plasmid vector and recombinant viruses were produced.

During viral transcription, the Cytomegalovirus enhancer promotes strong transcription from the chicken (Gallus gallus) beta-actin promoter and transcribes the Newcastle disease virus fusion protein (Protein F) before terminating at the Macaca mulatta polyomavirus 1 poly-adenylation signal.

The recombinant virus is sufficient to create immunity to Newcastle disease virus and Merek's disease virus (Gallid alphaherpesvirus 2).
LMO characteristics
Modified traits
Common use(s)
  • Vaccine
Detection method(s)
Additional information
Protein Detection:
The expression of NDV Protein F was confirmed using Southern blotting.